NEW YORK (GenomeWeb News) — William Blair today downgraded Sequenom after the San Diego-based company firm missed Wall Street estimates on the top and bottom lines in its second quarter.

After the earnings release shares of Sequenom were down as much as 56 percent today amid heavy trading.

Analyst Brian Weinstein downgraded Sequenom to Market Perform from Outperform and lowered his revenue estimate for full-year 2013 to $166.4 million from $200.4 million. He also lowered adjusted net loss estimates to $.87 per share from an earlier estimate of $.72 per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.